Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

(2017) Xiaoling Cai et al.   EXPERT OPINION ON PHARMACOTHERAPY

Clinical inertia to insulin initiation and intensification in the UK: A focused literature review

(2017) Kamlesh Khunti et al.   Primary Care Diabetes

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes

(2017) Virginia Valentine et al.   Diabetes Therapy

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes

(2017) Virginia Valentine et al.   Diabetes Therapy

Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation Approaches

(2017) Andrew Stokes et al.   PLoS One

Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs

(2016) Philip Levin et al.   CLINICAL THERAPEUTICS

Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin

(2016) K. Khunti et al.   DIABETES OBESITY & METABOLISM

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY

(2016) Alan J. Garber et al.   Endocrine Practice

Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

(2015) Sanjoy K Paul et al.   Cardiovascular Diabetology

Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes

(2015) Shi-Dou Lin et al.   Primary Care Diabetes

Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study

(2014) W. H. Polonsky et al.   DIABETES OBESITY & METABOLISM

Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus

(2014) W.D. Strain et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Assessing achievement and maintenance of glycemic control by patients initiating basal insulin

(2012) Ning Wu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Proportion of patients at HbA1c target

(2011) K. Esposito et al.   DIABETES OBESITY & METABOLISM

Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

(2010) Edith M. Heintjes et al.   ADVANCES IN THERAPY

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study

(2010) J. Gordon et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Insulin Therapy and Type 2 Diabetes: Management of Weight Gain

(2009) Samy I. McFarlane   Journal of Clinical Hypertension